Answers are grounded in this paper and cite their sources.
We demonstrate that DMI suppresses neuroinflammation and ameliorates disease severity in EAE through multiple cellular and molecular mechanisms, suggesting that DMI can be developed as a novel therapeutic agent for the treatment of MS/EAE through its immunomodulatory and anti-inflammatory properties.
No takes yet. Share an insight, caveat, or question.
Kuo et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: